saroglitazar inn trade name lipaglyn drug treatment type diabetes mellitus dyslipidemia approved use india drug controller general saroglitazar indicated treatment diabetic dyslipidemia hypertriglyceridemia type diabetes mellitus controlled statin therapy clinical studies saroglitazar demonstrated reduction triglycerides tg ldl cholesterol vldl cholesterol nonhdl cholesterol increase hdl cholesterol characteristic hallmark atherogenic diabetic dyslipidemia add also shown antidiabetic medication properties reducing fasting plasma glucose diabetes patients saroglitazar insulin sensitizer first class drug acts dual ppar agonist subtypes α alpha γ gamma peroxisome proliferatoractivated receptor ppar agonist action pparα lowers high blood triglycerides agonist action pparγ improves insulin resistance consequently lowers blood dual ppar agonist saroglitazar helps controlling blood glucose lipid parameters especially high triglycerides high nonhdl study done rats concluded saroglitazar potential prevent progression retinopathy diabetes using preclinical models also shown useful diabetic major serious adverse events reported however longterm cardiovascular safety concerns raised regarding increase serum creatinine use saroglitazar initially noted metaanalysis published dutta et al another randomized controlled trial published gawrieh et al mild significant increase serum creatinine noted weeks use saroglitazar dose december zydus discovery dmcc research subsidiary zydus lifesciences cited us fda deliberately misbranding saroglitazar december letter company us fda asked stop using broad statements worlds first stop suggesting drug approved throughout world including united states true httpsenwikipediaorgwikisaroglitazar